Table 3 Secondary endpoints

Variables

Full dose (n = 55)

Dose reduction (n = 58)

Differences between groups

P value

ASDAS-CRP < 1.3^a

61.4% [47.3%; 75.5%]

53.5% [39.7%; 67.3%]

7.8% [−10.0%; 25.8%]

0.389

ASDAS-CRP relapse^a

6.6% [−5.4%; 18.7%]

12.7% [1.4%; 24.0%]

−6.1% [−25.2%; 12.9%]

0.529

Relapse BASDAI-VAS^a

15.9% [−3.1%; 34.9%]

10.4% [−9.1%; 29.8%]

5.5% [−12.3%; 23.4%]

0.545

Relapse SER^a

6.4% [−13.0%; 25.8%]

10.1% [−7.9%; 28.1%]

− 3.7% [− 19.2%; 11.8%]

0.638

NSAIDs use^a

18.3% [− 1.2%; 37.7%]

20.6% [1.5%; 39.8%]

−2.4% [− 18.9%; 14.2%]

0.779

ASDAS-CRP score^b

1.1 (0.1) [0.9;1.3]

1.1 (0.1) [0.9;1.3]

0.0 (0.2) [−0.3;0.3]

0.783

BASDAI^b

1.4 (0.2) [1.1;1.7]

1.4 (0.2) [1.1;1.7]

− 0.0 (0.2) [− 0.5;0.4]

0.890

VAS night axial pain^b

1.4 (0.2) [1.0;1.8]

1.1 (0.2) [0.7;1.6]

0.3 (0.3) [−0.3;0.9]

0.337

PGA^b

1.6 (0.2) [1.2;2.0]

1.6 (0.2) [1.1;2.0]

0.0 (0.3) [−0.6;0.6]

0.962

IGA^b

1.1 (0.2) [0.8;1.4]

1.1 (0.2) [0.8;1.4]

−0.0 (0.2) [− 0.4;0.40]

0.923

BASFI^b

1.7 (0.2) [1.2;2.1]

1.8 (0.2) [1.3;2.3]

−0.2 (0.3) [− 0.8;0.5]

0.616

ASQoL^b

2.3 (0.5) [1.2;3.3]

2.2 (0.6) [1.0;3.3]

0.1 (0.7) [−1.3;1.5]

0.858

Adverse event or infections

Full dose (n = 62)

Dose reduction (n = 61)

Differences between groups

P value

Any^c

22 (35.5%) [23.6%;47.4%]

17 (27.9%) [16.6%;39.1%]

(7.6%) [−8.8%;24.0%]

0.439

Related^c

8 (12.9%) [4.6%;21.2%]

5 (8.2%) [1.3%;15.1%]

(4.7%) [−6.1%;15.5%]

0.559

Severe^c

14 (22.6%) [12.2%;33.0%]

11 (18.0%) [8.4%;27.7%]

(4.6%) [−9.6%;18.7%]

0.655

Severe and related^c

7 (11.3%) [3.4%;19.2%]

2 (3.3%) [−1.2%;7.7%]

(8%) [− 1.1%;17.1%]

0.164